Regenerative medicine is entering a pivotal phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative The...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended Ma...
The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...
In this exclusive BioPharma Boardroom interaction, Thierry Van Nieuwenhove, CEO of Quotient Sciences, explores why nearly 90% of drug candidates fail and w...
From a basement-born idea to a publicly traded biotech advancing late-stage clinical trials, Lew Bender’s journey reflects both scientific persistenc...
In this BioPharma Boardroom interview, Steven Quay, Founder and CEO of Atossa Therapeutics, outlines the scientific rationale behind developing (Z)-endoxif...
As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerat...
As life sciences companies scale biologics, advanced therapies, and personalized medicines, sustainability has moved from aspiration to operational imperat...
As biologic modalities grow more complex and timelines compress, the operational relationship between contract development and manufacturing organizations ...
Under the leadership of Joel Latham, Incannex Healthcare is advancing a differentiated pipeline of cannabinoid- and psychedelic-based thera...
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $1...
In this BioPharma Boardroom interview, Jason Causon, Senior Technical Product Manager for Accurate Mass Platforms at SCIEX, explores how multiomi...
Drug delivery is entering a period of rapid reinvention, driven as much by analytical innovation as by molecular design. In this BioPharma BoardRoo...
As mRNA technologies move rapidly beyond COVID-19 into vaccines and therapies for cancer, rare diseases, and personalized medicine, scientific complexity i...
© 2026 Biopharma Boardroom. All Rights Reserved.
